Waters Corp Presents Strategic Rationale and Synergies for BD Biosciences & Dx Acquisition at J.P. Morgan Conference

summarizeSummary

Waters Corporation presented an investor update at the J.P. Morgan Healthcare Conference, detailing the strategic rationale, significant cost and revenue synergies, and an industry-leading financial outlook for its proposed acquisition of BD Biosciences & Diagnostic Solutions.

check_boxKey Events

• Investor Presentation at J.P. Morgan Conference

  Waters Corporation delivered an investor presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, including high-level commentary on business performance.

• Strategic Rationale for BD Biosciences & Dx Acquisition

  The presentation detailed the strategic rationale for acquiring BD Biosciences & Diagnostic Solutions, highlighting its role in accelerating high-growth adjacencies and leveraging commercial scale.

• Significant Synergy Targets

  Waters projected $200 million in cost synergies and $290 million in revenue synergies ($145 million in Adjusted EBITDA) from the acquisition.

• Doubling Total Addressable Market

  The transaction is expected to double Waters' total addressable market (TAM) to $40 billion in attractive, growth-accretive markets.

auto_awesomeAnalysis

Waters Corporation used its presentation at the J.P. Morgan Healthcare Conference to provide a comprehensive overview of its proposed acquisition of BD Biosciences & Diagnostic Solutions. The company emphasized the strategic benefits, including doubling its total addressable market to $40 billion and accelerating growth in high-growth adjacencies. Management outlined substantial synergy targets, projecting $200 million in cost synergies and $290 million in revenue synergies, which are expected to significantly enhance the combined entity's financial performance. The presentation also provided an updated financial outlook, positioning the combined company for industry-leading revenue growth, EBIT margin expansion, and EPS growth. This detailed strategic and financial justification for a major transaction is highly material for investors.